Henry Schein (NASDAQ:HSIC) Issues FY 2024 Earnings Guidance

Henry Schein (NASDAQ:HSIC) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 4.740-4.820 for the period, compared to the consensus EPS estimate of 4.750. The company issued revenue guidance of $12.8 billion-$13.0 billion, compared to the consensus revenue estimate of $12.9 billion.

Henry Schein Trading Down 0.8 %

Shares of HSIC stock traded down $0.58 during trading on Thursday, hitting $69.43. 1,949,105 shares of the stock traded hands, compared to its average volume of 1,359,495. The firm has a market capitalization of $8.80 billion, a P/E ratio of 25.93, a price-to-earnings-growth ratio of 2.08 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.55 and a quick ratio of 0.90. The firm’s fifty day moving average price is $70.59 and its 200-day moving average price is $69.78. Henry Schein has a 52-week low of $62.12 and a 52-week high of $82.63.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.17 by $0.05. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The business’s revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.32 EPS. As a group, research analysts forecast that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HSIC has been the topic of a number of research analyst reports. Baird R W raised Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. Robert W. Baird cut their target price on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Barrington Research reissued an “outperform” rating and issued a $82.00 target price on shares of Henry Schein in a research report on Wednesday. Evercore ISI boosted their target price on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. cut their target price on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $77.50.

Insider Buying and Selling

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now owns 71,833 shares in the company, valued at approximately $4,978,026.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.14% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.